Table 3.
DMEs of Phase II and miRNAs that regulate their expression
| Target | miRNA | Model | Drug | Reference |
|---|---|---|---|---|
| UGT1A1 | miR-21-3p | NS | NS | Papageorgiou et al.[53], 2017 |
| miR-141-3p | ||||
| miR-200a-3p | ||||
| UGT2B4 | miR-216b-5p | HepG2 | Epirubicin | Dluzen et al.[51], 2016 |
| miR-135a | NS | NS | Wijayakumara et al.[54], 2017 | |
| miR-410 | ||||
| UGT2B7 | miR-3664 | |||
| UGT2B10 | miR216b-5p | Liver cancer | Epirubicin | Dluzen et al.[51], 2016 |
| UGT2B17 | miR-376c | NS | NS | Margaillan et al.[52], 2016 |
| GSTP1 | miR-133a | Head and neck, oesophageal, bladder | Cisplatin and carboplatin | Moriya et al.[50], 2012 |
| SULT1A1 | miR-631 | Breast cancer | Actinomycin D | Yu et al.[47], 2010 |
NS: not stated; DMEs: drug metabolizing enzymes